BG104175A - Метод за получаване на секретагоги на растежен хормон - Google Patents

Метод за получаване на секретагоги на растежен хормон Download PDF

Info

Publication number
BG104175A
BG104175A BG104175A BG10417500A BG104175A BG 104175 A BG104175 A BG 104175A BG 104175 A BG104175 A BG 104175A BG 10417500 A BG10417500 A BG 10417500A BG 104175 A BG104175 A BG 104175A
Authority
BG
Bulgaria
Prior art keywords
formula
compound
oxo
acid
methyl
Prior art date
Application number
BG104175A
Other languages
Bulgarian (bg)
English (en)
Inventor
Frank BUSCH
Charles Chiu
Clifford MELTZ
Ronald POST
Peter Rose
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG104175A publication Critical patent/BG104175A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG104175A 1999-02-26 2000-02-22 Метод за получаване на секретагоги на растежен хормон BG104175A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12274599P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
BG104175A true BG104175A (bg) 2000-12-29

Family

ID=22404505

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104175A BG104175A (bg) 1999-02-26 2000-02-22 Метод за получаване на секретагоги на растежен хормон

Country Status (44)

Country Link
US (2) US6541634B2 (ko)
EP (2) EP1031575B1 (ko)
JP (3) JP3437813B2 (ko)
KR (2) KR100372063B1 (ko)
CN (3) CN1515570A (ko)
AP (1) AP1221A (ko)
AR (2) AR029617A1 (ko)
AT (1) ATE277944T1 (ko)
AU (1) AU764122B2 (ko)
BG (1) BG104175A (ko)
BR (2) BRPI0017522B8 (ko)
CA (1) CA2299495C (ko)
CO (1) CO5160252A1 (ko)
DE (1) DE60014212T2 (ko)
DK (1) DK1031575T3 (ko)
DZ (1) DZ3018A1 (ko)
EA (1) EA003218B1 (ko)
EE (1) EE200000193A (ko)
ES (1) ES2226712T3 (ko)
GT (1) GT200000018A (ko)
HK (1) HK1030219A1 (ko)
HN (1) HN2000000021A (ko)
HR (1) HRP20000103A2 (ko)
HU (1) HUP0000907A3 (ko)
ID (1) ID24861A (ko)
IL (2) IL134599A (ko)
IN (1) IN192352B (ko)
IS (1) IS5380A (ko)
MA (1) MA25072A1 (ko)
NO (1) NO20000965L (ko)
NZ (1) NZ503062A (ko)
OA (1) OA11325A (ko)
PA (1) PA8491201A1 (ko)
PE (1) PE20001550A1 (ko)
PL (1) PL338628A1 (ko)
PT (1) PT1031575E (ko)
SG (1) SG90096A1 (ko)
SI (1) SI1031575T1 (ko)
SK (1) SK284982B6 (ko)
TN (1) TNSN00035A1 (ko)
TR (1) TR200000536A2 (ko)
TW (2) TWI286142B (ko)
UA (1) UA70306C2 (ko)
ZA (1) ZA200000888B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
WO2004103983A1 (en) * 2003-05-26 2004-12-02 Biocon Limited Process for the preparation of s(+)-2-ethoxy-4-[n-{1-(2-piperidinophelyl)-3-methyl-1- butyl} aminocarbonylmethyl]benzoic acid derivatives
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US9117477B2 (en) 2013-05-08 2015-08-25 HGST Netherlands B.V. Perpendicular magnetic recording media having novel seed layer
US9499543B2 (en) * 2013-05-28 2016-11-22 Raqualia Pharma Inc. Polymorph forms
CN109320515A (zh) * 2018-11-22 2019-02-12 常州大学 一种Capromorelin手性中间体的不对称合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
CA2175218A1 (en) 1993-11-09 1995-05-18 Gregori J. Morriello Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5609150A (en) 1995-04-18 1997-03-11 Maged; Jeffrey M. Method for dilating respiratory passages
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1997034604A1 (en) 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
WO1997036873A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
UA64751C2 (uk) * 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
USRE38524E1 (en) 1997-06-25 2004-06-01 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
TWI286142B (en) 2007-09-01
HN2000000021A (es) 2001-02-02
ATE277944T1 (de) 2004-10-15
KR20010006698A (ko) 2001-01-26
PA8491201A1 (es) 2001-04-30
NO20000965L (no) 2000-08-28
CN1515570A (zh) 2004-07-28
US6541634B2 (en) 2003-04-01
TNSN00035A1 (fr) 2005-11-10
ES2226712T3 (es) 2005-04-01
PL338628A1 (en) 2000-08-28
TW200718702A (en) 2007-05-16
DZ3018A1 (fr) 2004-03-20
KR100372063B1 (ko) 2003-02-14
SK2302000A3 (en) 2000-11-07
EP1031575A1 (en) 2000-08-30
NZ503062A (en) 2001-07-27
HU0000907D0 (en) 2000-04-28
KR20020065455A (ko) 2002-08-13
UA70306C2 (en) 2004-10-15
CN1837205A (zh) 2006-09-27
TR200000536A2 (tr) 2000-09-21
DE60014212D1 (de) 2004-11-04
BRPI0017522B8 (pt) 2021-05-25
IL157103A (en) 2007-07-24
HK1030219A1 (en) 2001-04-27
HUP0000907A3 (en) 2001-05-28
ZA200000888B (en) 2001-08-23
PT1031575E (pt) 2004-11-30
CA2299495A1 (en) 2000-08-26
KR100361783B1 (ko) 2002-11-22
DK1031575T3 (da) 2005-01-03
SG90096A1 (en) 2002-07-23
PE20001550A1 (es) 2001-01-11
US20030158414A1 (en) 2003-08-21
JP2000247974A (ja) 2000-09-12
IL134599A0 (en) 2001-04-30
BRPI0017522A2 (ko) 2009-12-22
JP3437813B2 (ja) 2003-08-18
DE60014212T2 (de) 2005-12-15
NO20000965D0 (no) 2000-02-25
JP2003327585A (ja) 2003-11-19
BRPI0000967B8 (pt) 2021-12-07
HRP20000103A2 (en) 2001-04-30
AR029617A1 (es) 2003-07-10
CO5160252A1 (es) 2002-05-30
ID24861A (id) 2000-08-31
CA2299495C (en) 2010-06-15
HUP0000907A2 (en) 2001-03-28
JP4051314B2 (ja) 2008-02-20
OA11325A (en) 2003-10-27
US20020002283A1 (en) 2002-01-03
AR053722A2 (es) 2007-05-16
BRPI0000967B1 (pt) 2012-06-12
SI1031575T1 (en) 2005-02-28
AU1947100A (en) 2000-08-31
US6673929B2 (en) 2004-01-06
MA25072A1 (fr) 2000-10-01
IL157103A0 (en) 2004-02-08
BRPI0017522B1 (pt) 2013-09-24
AP2000001754A0 (en) 2000-03-31
EE200000193A (et) 2000-10-16
EP1031575B1 (en) 2004-09-29
IN192352B (ko) 2004-04-10
JP2003261565A (ja) 2003-09-19
CN1270960A (zh) 2000-10-25
AU764122B2 (en) 2003-08-07
EA003218B1 (ru) 2003-02-27
BRPI0000967A (pt) 2001-09-11
GT200000018A (es) 2001-08-16
EA200000172A3 (ru) 2000-10-30
EA200000172A2 (ru) 2000-08-28
IL134599A (en) 2006-12-10
EP1449842A1 (en) 2004-08-25
CN1137891C (zh) 2004-02-11
IS5380A (is) 2000-08-27
AP1221A (en) 2003-11-03
SK284982B6 (sk) 2006-03-02

Similar Documents

Publication Publication Date Title
JP7185532B2 (ja) 免疫調節化合物
EP3952902A1 (en) Dosage forms and regimens for amino acid compounds
KR20200139676A (ko) 아미노산 화합물 및 사용 방법
AU718584B2 (en) New arylglycinamide derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
WO2010131663A1 (ja) オキサミド誘導体
BG104175A (bg) Метод за получаване на секретагоги на растежен хормон
US20020010335A1 (en) Process and intermediates for growth hormone secretagogues
US7244734B2 (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
CZ2000704A3 (cs) Způsob přípravy sloučenin podporujících sekreci růstového hormonu
IL108829A (en) Enzymatic process for the preparation of R2 Trans (alkyl2-piperidinecarboxylates with optical purification and the use of a compound obtained as an intermediate in synthesis
TW202308637A (zh) 整合素抑制劑之擴大劑量方案
MXPA00002031A (en) Process for preparing growth hormone secretagogues
RU2797345C2 (ru) Новые соединения пиридинов и пиразинов в качестве ингибиторов каннабиноидного рецептора 2